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KEY POINTS
• GA101 is a novel type II anti-CD20 monoclonal antibody under early-stage clinical investigation
• GA101 plus CHOP or FC has an acceptable safety profile and is effective in relapsed/refractory follicular lymphoma
INTRODUCTION
Rituximab-based immunochemotherapy is the backbone of treatment for nonHodgkin's lymphoma (NHL). 1 Compared with chemotherapy, immunochemotherapy provides significant, sustained clinical benefits, including prolonged survival in patients with aggressive NHL, [2] [3] [4] indolent NHL (iNHL), [5] [6] [7] [8] [9] [10] [11] and chronic lymphocytic leukemia (CLL). 12, 13 Many patients who initially benefit from rituximab-based immunochemotherapy relapse, and some fail to respond. There is, therefore, a need to develop therapies with improved antitumor activity and better risk/benefit profiles for optimal treatment of B-cell malignancies.
Obinutuzumab (GA101) is a type II CD20-targeted monoclonal antibody (mAb) with enhanced direct cell death induction but reduced complement-dependent cytotoxicity. 14 GA101 has been glycoengineered to decrease the fucose content of the Fc region, which increases its affinity for FcγRIIIa on effector cells, even lowaffinity receptor variants. Consequently, antibody-dependent cell-mediated cytotoxicity is increased. 14, 15 In vitro studies have demonstrated different mechanisms of action for rituximab (type I nonglycoengineered mAb) and GA101
(type II glycoengineered mAb), despite both targeting the same antigen and having overlapping epitopes. 14 Molecular differences between type I and type II mAbs and how they bind to their epitopes may lead to different functional properties; preclinical studies have demonstrated the superiority of GA101 over rituximab and ofatumumab (type I mAbs) in killing lymphoma cells, 14 with increases in direct cell death via caspase-independent, nonapoptotic, lysosomal mechanisms. 16 The increased antitumor activity of GA101 in human xenograft models has also been shown. 14, 17 For personal use only. on April 10, 2017. by guest www.bloodjournal.org From Phase 1 and phase 2 studies in patients with NHL have demonstrated promising activity from single-agent GA101. [18] [19] [20] [21] Here we report the results of the phase 1b GAUDI study (BO21000), which explored the safety and activity of 2 doses of GA101 combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or fludarabine and cyclophosphamide (FC) as induction therapy in patients with relapsed/refractory follicular lymphoma (FL).
METHODS
Study Design
GAUDI was an open-label, multicenter, phase 1b study composed of patients with was at investigator discretion and based on the patient's treatment history; the protocol required 28 patients to be treated with each chemotherapy regimen.
Following assignment to G-CHOP or G-FC, patients were randomized to either GA101 1,600/800 mg (1,600 mg on days 1 and 8 of cycle 1, 800 mg on day 1 of subsequent cycles) or GA101 400/400 mg (400 mg on days 1 and 8 of cycle 1, day 1 of subsequent cycles). These doses were based on previous pharmacokinetic analyses. 18 Patients achieving complete responses (CR) or partial responses (PR) after induction were eligible for GA101 maintenance therapy administered at the induction dose (every 3 months for up to 2 years or until progression). 
Treatment
GA101 was infused on days 1 and 8 of cycle 1 and day 1 of subsequent cycles as previously described. 18 Patients were premedicated with acetaminophen and an antihistamine before GA101 infusion. The first 3 patients in each cohort were restricted to GA101 400/400 mg and monitored until day 15 for significant unexpected adverse events (AEs). When none were observed, randomization Responses were assessed based on computed tomography scan. Positron emission tomography scans were exploratory. Unconfirmed CRs were considered PRs per revised response criteria for malignant lymphoma.
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Statistical Analysis
After physicians assigned patients to G-CHOP or G-FC, patients were randomized to GA101 400/400 mg or 1,600/800 mg. All patients who received ≥ 1 GA101 dose were analyzed for safety and efficacy. Baseline and demographic characteristics are summarized descriptively. Patients with CR or PR were regarded as responders.
Response rates and 95% Clopper-Pearson confidence intervals (CIs) were estimated for each GA101 dose group and chemotherapy regimen. Statistical analyses were conducted using SAS (SAS Institute Inc, Cary, NC) or S-PLUS (Tibco Software, Inc, Palo Alto, CA).
For personal use only. on April 10, 2017. by guest www.bloodjournal.org From
RESULTS
Patient Characteristics
Fifty-six patients with relapsed/refractory FL received GA101 plus CHOP (n = 28) or FC (n = 28) ( Table 1) 
Patient Disposition and Treatment Exposure
All patients receiving G-CHOP completed induction ( Figure 1 ). Two patients (14%) from the G-FC 400/400-mg arm discontinued therapy owing to adverse events (AEs). Four (29%) from the G-FC 1,600/800-mg arm discontinued owing to AEs (n = 3) or insufficient response (n = 1). In both G-CHOP arms, all patients received ≥ 6 treatment cycles. In the G-FC arms, most patients received the minimum 4 cycles of therapy. Two patients in each dose group withdrew during cycles 1-3. Two additional patients withdrew from the high dose group during cycles 4-6.
Safety
In the G-CHOP cohort, the most frequent treatment-related hematologic AE was neutropenia (400/400 mg, 29%; 1,600/800 mg, 57%; Table 2 ). Grade 3/4 neutropenia was documented in 29% and 50% of patients in the 400/400-mg and 1,600/800-mg arms, respectively, lasting, on average, 9 days. One patient (7%) in the G-CHOP 1,600/800-mg dose group experienced febrile neutropenia; the event was grade 3/4. Most patients with grade 3/4 neutropenia (7/11) received G-CSF support; other grade 3/4 hematologic AEs were not experienced by >1 patient. The most common treatment-related non-hematologic AE was IRRs (64% in both G-CHOP arms; Table 3 ). The 1,600/800-mg G-CHOP arm had a higher infection incidence than the 400/400-mg arm (57% versus 29%), but grade 3/4 infection incidences were identical for both doses (3 patients each, 21%). Eight patients ( In the G-FC cohort, the most frequent hematologic AE was neutropenia (400/400 mg, 64%; 1,600/800 mg, 36%, all were grade 3/4). Two patients (14%) in the 1,600/800-mg arm experienced febrile neutropenia (Table 2) , lasting 7 and 10 days.
Twelve of 14 (86%) patients with grade 3/4 neutropenia received G-CSF support.
Seven patients (25%) had grade 3/4 thrombocytopenia, with a median duration of 15 days; 1 patient required treatment. Grade 3/4 anemia occurred in 2 patients in the 400/400-mg arm. The most frequent treatment-related nonhematologic AE was IRR occurring in 71% and 86% in the 400/400-mg and 1,600/800-mg arms, respectively (Table 3) . Infection incidences were higher in the 1,600/800-mg than 400/400-mg arm (all grades: 43% versus 21%; grade 3/4: 29% versus 7%, respectively). Table 4 .
Serious AEs (SAEs) were reported in 29% and 25% of patients in the G-CHOP and G-FC cohorts, respectively. There were no relevant differences in specific infections between arms in each cohort. No treatment-related deaths were reported.
IRRs occurred mainly during first infusion (8 patients in each dose arm for G-CHOP;
10 patients in each dose arm for G-FC). No more than 3 patients in either cohort experienced IRRs at any subsequent infusion. One patient in each cohort experienced a grade 3/4 IRR. All patients received the planned full dose of GA101.
Three patients were positive for anti-rituximab HACAs at screening, which was confirmed on second testing (2 patients, G-CHOP; 1 patient, G-FC); all responded to treatment. At treatment end, no patient had detectable HAHAs, including the 1 patient who had tested positive at screening. 
Pharmacokinetics
In both cohorts, the 1,600/800-mg arms had higher mean GA101 serum concentrations than the 400/400-mg arms (Figure 2) . Patients who achieved CR had higher mean serum GA101 concentrations than patients with PR, which remained higher throughout treatment (data not shown).
Pharmacodynamics
As expected in a relapsed/refractory setting, patients had low baseline B-cell counts CHOP. In the EORTC 20981 study, which enrolled patients with FL in first relapse, SAEs were observed in 27% and 30% of patients treated with CHOP and R-CHOP, respectively. In EORTC 20981, 48% and 55% of patients given CHOP and R-CHOP, respectively, experienced grade 3/4 neutropenia, 10,24 which is comparable with the 39% incidence observed in the G-CHOP cohort in our study.
No new safety signals were seen in the G-FC arms versus previous trials of rituximab plus fludarabine, cyclophosphamide, and mitoxantrone (FCM) in patients with relapsed FL or mantle cell lymphoma 6 or in patients with FL treated with first-line fludarabine, cyclophosphamide, and rituximab (FCR) followed by maintenance therapy. 25 However, G-FC was less well tolerated than G-CHOP. The less favourable AE profile seen with G-FC may be the consequence of the small sample size, especially since tolerability seemed better for G-FC 1,600/800 mg than G-CHOP 400/400 mg, or to differences in the 2 patient populations (G-FC-treated patients were more extensively pretreated, with a longer median time from diagnosis). Yet, FC-related tolerability issues have been previously reported. In the ECOG 1496 study comparing FC with cyclophosphamide, vincristine, and prednisone (CVP) in previously untreated patients with indolent lymphoma, recruitment to the FC arm was halted after 8 deaths occurred during induction.
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G-chemotherapy efficacy data are encouraging, and response rates, particularly CR rates, compare favorably with previous reports of R-chemotherapy in patients with relapsed disease. 6, 10, 24 In a study of rituximab-naïve patients with relapsed/refractory FL administered R-CHOP, 30% achieved CR at treatment end. 24 In GAUDI, where all but 1 patient was rituximab-experienced, 39% of G-CHOP-treated patients had
CR. Moreover, all 14 patients with rituximab-refractory disease in GAUDI responded
For personal use only. on April 10, 2017. by guest www.bloodjournal.org From 15 to treatment, including 4 CRs. A clear dose-response relationship was not apparent in this limited patient series. The CR rate was higher for G-CHOP 1,600/800 mg than G-CHOP 400/400 mg, but the opposite was observed for G-FC. This may have been due to differences in tumor loads: 4 patients in the G-FC 1600/800-mg arm had a sum of the product of diameters >10,000 mm 2 ; all had PRs.
Mean GA101 serum concentrations were higher in both G-chemotherapy 1,600/800-mg arms compared with the 400/400-mg arms. Regardless of chemotherapy backbone, mean GA101 serum concentrations from cycle 2 onward were higher in patients with CR than those with PR, suggesting that individuals with CR maintain high GA101 serum concentrations and may eliminate GA101 more slowly, possibly reflecting shrinking tumor load. 27 Whether GA101 serum concentration is also correlated to baseline tumor bulk has not been investigated due to the small sample size and heterogeneity of the study population. In patients with iNHL administered GA101 monotherapy, the difference in end-of-treatment response rates between the 400/400-mg and 1,600/800-mg dose groups was significant (38%; 95% CI, 7.4%-68.4%). 21 These results, in addition to pharmacokinetic and preclinical data suggesting that higher GA101 doses and use of loading doses would rapidly increase and sustain GA101 serum concentrations, [28] [29] [30] Patients who responded to therapy in the GAUDI study were eligible to receive maintenance therapy. Thus, additional response and time-dependent end points will be reported. Based on the currently available data, G-CHOP-regardless of doseappears to have a safety profile similar to R-CHOP, the current standard of care for Prior treatment lines, median (range)
Refractory to last treatment, n (%) 1 (7) 4 (29) 5 (18) 2 (14) 5 (36) 7 (25) Prior rituximab treatment lines, median (range)
Rituximab-refractory, n (%) 1 ( Infusion-related reaction 1 (7) 1 (7) 2 (7) 1 (7) 1 (7) 2 (7) Vomiting 1 (7) 1 (7) 2 For personal use only. on April 10, 2017. by guest www.bloodjournal.org From
